The Federal Trade Commission will require Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. The settlement is the latest FTC action taken to preserve competition and protect U.S. consumers from higher health care costs. […]